LOGIN  |  REGISTER
Cue Biopharma

Premier to Report Fiscal 2025 Second-Quarter Results and Host Conference Call on February 4, 2025

January 16, 2025 | Last Trade: US$20.46 0.05 0.24

CHARLOTTE, N.C. / Jan 16, 2025 / Business Wire / Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2025 second quarter on Tuesday, February 4, 2025, at approximately 6:30 a.m. ET. The company will also host a conference call at 8:00 a.m. ET to discuss its financial results.

The live webcast and replay will be available in the Investors section of the company’s website at Events & Presentations. The webcast should be accessed 10 minutes prior to the conference call start time. The replay of the event will be available for one year following the conclusion of the live broadcast.

For those parties who do not have internet access, the conference call can be accessed by calling one of the below telephone numbers and asking to join the Premier, Inc. call:

Domestic participant dial-in number (toll-free):

(833) 953-2438

International participant dial-in number:

(412) 317-5767

About Premier, Inc.

Premier, Inc. (NASDAQ: PINC) is a leading technology-driven healthcare improvement company, providing solutions to two-thirds of all healthcare providers in the U.S. Playing a critical role in the rapidly evolving healthcare industry, Premier unites providers, suppliers, payers and policymakers to make healthcare better with national scale, smarter with actionable intelligence and faster with novel technologies. Headquartered in Charlotte, N.C., Premier offers integrated data and analytics, collaboratives, supply chain solutions, consulting and other services in service of our mission to improve the health of communities. Please visit Premier’s news and investor sites on www.premierinc.com, as well as X, Facebook, LinkedIn, YouTube, Instagram and Premier’s blog for more information about the company.

Terns Pharmaceuticals

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page